← All trials
NCT05821231
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2023
- Primary completion
- Nov 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- Apr 20, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ToulouseLead sponsor
- AstraZenecaCollaborator
- National Cancer Institute, FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.